What is DalCor Pharmaceuticals?
DalCor Pharmaceuticals is a biopharmaceutical innovator focused on the development of precision medicine for cardiovascular diseases. The company's flagship asset, dalcetrapib, represents a novel pharmacogenetic approach designed to mitigate the risk of recurrent myocardial infarction. By specifically targeting patients with the AA genotype at the rs1967309 location in the ADCY9 gene, DalCor is pioneering a personalized treatment paradigm. Currently, the company is advancing its clinical agenda through the Dal-GenE-2 Phase 3 trial, aiming to provide a tailored therapeutic solution for high-risk populations, including those managing obesity, diabetes, and hypertension.
How much funding has DalCor Pharmaceuticals raised?
DalCor Pharmaceuticals has raised a total of $230M across 3 funding rounds:
Series A
$50M
Series B
$100M
Series D
$80M
Series A (2015): $50M with participation from Sanderling Ventures, Caisse de du00e9pu00f4t et placement du Quu00e9bec, CTI Life Sciences, and Fonds de solidaritu00e9 FTQ
Series B (2016): $100M led by Fonds de solidaritu00e9 FTQ, CTI Life Sciences, Caisse de du00e9pu00f4t et placement du Quu00e9bec, and Sanderling Ventures
Series D (2023): $80M supported by Fonds de Developpement Économique and TB Alliance
Key Investors in DalCor Pharmaceuticals
CTI Life Sciences
A prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, with a strong emphasis on cardiology and rare diseases.
Caisse de dépôt et placement du Québec
A full-service institutional portfolio investment company that manages public and private pension and insurance funds, providing long-term capital for strategic growth.
Sanderling Ventures
A pioneering investment firm specializing in building new biomedical companies through early-stage financing and active management of small molecule therapeutics and platform technologies.
What's next for DalCor Pharmaceuticals?
With the recent capital infusion, DalCor Pharmaceuticals is well-positioned to accelerate its Phase 3 clinical trials and refine its commercialization strategy. The focus remains on validating the efficacy of dalcetrapib within the identified patient cohort, a critical step toward regulatory approval and market entry. As the company transitions from a research-heavy entity to a late-stage clinical organization, the strategic deployment of these funds will be pivotal in scaling operations and ensuring the successful execution of its global clinical program. Future growth will likely hinge on the successful readout of the Dal-GenE-2 study, which could redefine standard-of-care protocols for patients with specific genetic predispositions to cardiovascular events.
See full DalCor Pharmaceuticals company page
